For laboratory and research use only. Not for human consumption.
Growth Hormone

Ipamorelin

Also known as: IPAM, NNC 26-0161

Clinical Trials
Share:
Last reviewed

Buy in shop

Ipamorelin

5 verified vendors, side by side on real prices.

Compare prices

Key Facts: Ipamorelin

Category
Growth Hormone
FDA Status
Not FDA Approved
Clinical Status
Investigational - Phase II trials discontinued. Never FDA approved for any human indication. Its FDA 503A status changed during 2026, but ipamorelin has not been added to the 503A bulks list and so remains ineligible for 503A compounding, and it stays on the 503B Category 2 list for outsourcing facilities.
Banned in Sport (WADA)
Prohibited at all times under WADA S2 (growth hormone secretagogues), named on the list.
Administration
Subcutaneous injection
Typical Dose
200-300 mcg 2-3x daily
Frequency
2-3x daily
Duration
8-12 weeks typical
Also Known As
IPAM, NNC 26-0161

How does Ipamorelin work?

Ipamorelin is an agonist of the ghrelin / growth hormone secretagogue receptor (GHS-R1a) on the somatotroph cells of the anterior pituitary. Binding this receptor triggers intracellular signaling (Gq/phospholipase C, IP3 and calcium release) that makes the pituitary release stored GH in pulses, mimicking natural ghrelin. Its defining feature, established in the original 1998 characterization, is selectivity: at GH-releasing doses it does not meaningfully raise ACTH, cortisol, prolactin, FSH, LH or TSH, making it cleaner than older peptides like GHRP-2 and GHRP-6. Because it works on the pituitary's own GH reserves, the effect depends on a functioning pituitary and natural feedback loops stay in place.

What does the research show?

The foundational work is Raun et al. (1998) in the European Journal of Endocrinology, which characterized ipamorelin in rats, pigs and isolated pituitary cells and named it the first selective growth hormone secretagogue, releasing GH without raising ACTH or cortisol even at doses far above the GH-releasing dose. Most rigorous data is preclinical. In humans, the compound was advanced into Phase II trials for postoperative ileus but was discontinued for insufficient efficacy. There are no large peer-reviewed human randomized controlled trials supporting the popular anti-aging, fat-loss, muscle-gain or recovery claims; those uses are extrapolations from the mechanism, not proven outcomes. Honestly stated: the receptor mechanism and GH-release effect are well documented, but human efficacy and long-term safety for wellness use are not established.

Trial Progress:Phase II
Pre
I
II
III
IV
FDA

What doses have been studied?

Human Trials·Human studies conducted, not FDA approved

Typical Dosingⓘ

Community experience

Common Dose

200-300 mcg 2-3x daily

Range

100-500 mcg per dose

Frequency

2-3x daily

Reported protocols administer in a fasted state, most often in the morning, after exercise, or before sleep, and frequently alongside CJC-1295.

Research Dosingⓘ

Scientific studies

Doses observed in research studies

Duration

8-12 weeks typical

Administration

Subcutaneous injection

When and how is Ipamorelin taken?

Best Time to Take

Before bed or morning (fasted)

2-3 times daily, with main dose before bed

Food Recommendation

Take on empty stomach

Why This Timing?

GH secretagogues work best when taken fasted, as food (especially carbs/fats) blunts GH release. Evening dosing aligns with natural GH pulses during sleep.

What are the side effects of Ipamorelin?

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • ●Generally well-tolerated
  • ●Injection site reactions
  • ●Headache
  • ●Nausea
  • ●Increased appetite
  • ●Water retention
  • ●Joint stiffness (temporary)
  • ●Does not significantly elevate cortisol or prolactin
  • ●Contraindicated with active malignancy

References

Research This Peptide Further

Buy in shop

Ipamorelin

5 verified vendors, side by side on real prices.

Compare prices

Frequently Asked Questions

What does Ipamorelin do?

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed by Novo Nordisk and derived from GHRP-1. It is researched mainly for stimulating the body's own growth hormone (GH) release, and was studied in humans primarily for postoperative ileus and gut motility rather than anti-aging. It is not an approved drug anywhere: it reached Phase II trials, was discontinued for insufficient efficacy, and is now sold only as a research chemical.

How does Ipamorelin work?

Ipamorelin is an agonist of the ghrelin / growth hormone secretagogue receptor (GHS-R1a) on the somatotroph cells of the anterior pituitary. Binding this receptor triggers intracellular signaling (Gq/phospholipase C, IP3 and calcium release) that makes the pituitary release stored GH in pulses, mimicking natural ghrelin. Its defining feature, established in the original 1998 characterization, is selectivity: at GH-releasing doses it does not meaningfully raise ACTH, cortisol, prolactin, FSH, LH or TSH, making it cleaner than older peptides like GHRP-2 and GHRP-6. Because it works on the pituitary's own GH reserves, the effect depends on a functioning pituitary and natural feedback loops stay in place.

Is Ipamorelin FDA approved?

No, Ipamorelin is not currently FDA approved. Current status: Investigational - Phase II trials discontinued. Never FDA approved for any human indication. Its FDA 503A status changed during 2026, but ipamorelin has not been added to the 503A bulks list and so remains ineligible for 503A compounding, and it stays on the 503B Category 2 list for outsourcing facilities.

Is Ipamorelin banned in sport?

Prohibited at all times under WADA S2 (growth hormone secretagogues), named on the list.

What are the side effects of Ipamorelin?

Reported side effects include: Generally well-tolerated, Injection site reactions, Headache, Nausea, Increased appetite. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Ipamorelin?

Community-reported common dose: 200-300 mcg 2-3x daily (2-3x daily). Range: 100-500 mcg per dose. Administration: Subcutaneous injection. Community-reported doses. Not medical advice. Consult healthcare provider.

Related Peptides

Peptides commonly compared with Ipamorelin or used in similar applications.

GHRP-6

Clinical Trials

GHRP-6 is a synthetic six-amino-acid peptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that tricks the body into releasing its own growth hormone. It was one of the first growth hormone secretagogues ever made, and the hunt to find out why it worked led scientists straight to the discovery of ghrelin. It has no approval as a drug anywhere and is used only as a research compound.

Growth Hormone

CJC-1295 (No DAC)

Clinical Trials

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically a modified GHRH(1-29). The name covers two different products. CJC-1295 with DAC (Drug Affinity Complex) binds blood albumin, which stretches its half-life to roughly 6 to 8 days and raises GH and IGF-I for days from a single injection; this is the version ConjuChem took to Phase II before abandoning it, and the version the human data are about. CJC-1295 without DAC (Modified GRF 1-29, the form this page is named for) lacks the albumin tether and is much shorter acting, though its human half-life has not been formally published. Neither is an approved drug, both are sold only as research chemicals, and GHRH analogs are banned in sport by WADA.

Growth Hormone

GHRP-2

Clinical Trials

GHRP-2 (generic name pralmorelin) is a synthetic hexapeptide growth hormone secretagogue and a second-generation cousin of GHRP-6. It prompts the pituitary to release growth hormone and is the one peptide in this family with an actual regulatory approval: it is licensed in Japan as a diagnostic agent for growth hormone deficiency. Outside that narrow diagnostic use it has no approval and is sold elsewhere only as a research compound.

Growth Hormone

MK-677

Clinical Trials

MK-677 (ibutamoren) is not actually a peptide, it is a small, orally active non-peptide molecule that mimics ghrelin, your hunger and growth-hormone hormone. Taken as a daily pill, it reliably pushes up growth hormone and IGF-1 levels, which is why it is popular for muscle and recovery. It has been through real human trials but was never approved as a drug, and the trials that mattered most for older adults and Alzheimer's came up short.

Growth Hormone

HGH (Somatropin)

FDA

Human growth hormone is the real thing rather than a secretagogue: a 191-amino-acid protein identical to what your pituitary makes, produced recombinantly since the 1980s. It is a properly approved medicine for growth hormone deficiency, and it is also the most misused compound in this entire space. Almost everything you read about HGH for anti-aging or physique traces back to a single small 1990 study whose own author later disowned how it was used.

Growth Hormone

Tesamorelin

FDA

Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH 1-44) with a chemical modification that protects it from rapid breakdown. It is FDA-approved (brand name Egrifta) to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy, which makes it one of the few growth-hormone-axis peptides with a real approval behind it. Its evidence base is solid for that specific population and thinner for the general anti-aging and fat-loss uses it gets promoted for online.

Growth Hormone

Want updates on Ipamorelin research?

Get an email when we add new research here, when it is back in stock, or when the price drops.